Exercise to Prevent AnthrCycline-based Cardio-Toxicity Study

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
NeoplasmsHeart; Disease, FunctionalInflammation
Interventions
OTHER

Moderate Intensity Exercise

Exercise sessions will be held twice-weekly and will begin with a group warm-up activity, followed by 45 minutes of aerobic activity and ending with a cool down. All aerobic exercise will be performed at a moderate intensity, defined as exercise that elicits a heart rate (HR) between 40-60% of heart rate reserve (HRR). Prior to the initial exercise session target heart rates will be calculated for each subject based on the maximum HR achieved during their baseline stress test.

Trial Locations (1)

B3H 3A7

QEII Health Science Center, Nova Scotia Health Authority, Halifax

All Listed Sponsors
lead

Nova Scotia Health Authority

OTHER

NCT02471053 - Exercise to Prevent AnthrCycline-based Cardio-Toxicity Study | Biotech Hunter | Biotech Hunter